Eurofins BioPharma Services Newsletter 29 - June 2021

ARTICLES:
- ddPCR in GMP product testing quantifies without calibration curve & determines absolute DNA concentration
- Coumarin in cosmetics: Clarifying the safety controversy
- Nanomilling for bioavailability enhancement: New capabilities at Eurofins CDMO in North America
- Eurofins utilises ultrasensitive methods in the battle against neurodegeneration
- Analytical Quality by Design: Eurofins BPT France delivers new level of expertise for methods development
- Eurofins Biomnis is helping psychiatrists to optimise the choice of antidepressants in the treatment of depression
Download the PDF version of pharma newsletter N°29